Skip to main content


By November 25, 2020No Comments

Toronto, OntarioMarch 26, 2015SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),

announced that after dealing with certain matters, including the appointment of auditors, its annual and special meeting of shareholders held on March 26, 2015 (the “Meeting”) was adjourned, as previously disclosed on March 25, 2015, until April 8, 2015 at 11:00 a.m. (Toronto time). The date of the reconvened Meeting has been changed from that previous disclosed. The Meeting will reconvene at the offices of the Company’s counsel, Gowling Lafleur Henderson LLP, located at 100 King Street West, Suite 1600, Toronto, Ontario.

The voting on the adjournment motion at the Meeting was conducted by way of a ballot. The Meeting was adjourned with 39, 868,762 (100%) votes cast in favour of adjournment and no votes cast against. The deadline for the deposit of proxies has been extended to 11:00 a.m. (Toronto time) on April 6, 2015. Shareholders who wish to vote, revoke or amend their proxies can follow the procedures set out in the management proxy circular of the Company dated February 25, 2015 which can be found on and will be permitted to make changes until the revised proxy cut-off deadline. Beneficial shareholders who wish to attend the Meeting and vote their shares in person should follow the instructions set out in their Voting Information Forms. Beneficial shareholders who have already submitted their Voting Information Forms and wish to amend or revoke their instructions should contact their intermediary to provide a control number or request a new Voting Information Form.

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company’s proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit

Investor Relations Contact:

Chief Executive Officer
Andrew Morris
416.674.9500 ext. 229

Chief Financial Officer
Lennie Ryer
416.674.9500 ext. 241


This news release contains certain forward-looking statements, including, without limitation, statements containing the words “will”, “to be” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.